However, KRASG12C only accounts for 25% to 43% of all oncogenic KRAS mutations in NSCLC patients,6,7,14 and the remaining KRAS mutant subtypes (such as KRASG12D, KRASG12S, KRASG12V, and KRASQ61H) present distinct biological challenges. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.